Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders.

Current diagnostic standards for lymphoproliferative disorders include multiple tests for detection of clonal immunoglobulin (IG) and/or T-cell receptor (TCR) rearrangements, translocations, copy-number alterations (CNAs), and somatic mutations. The EuroClonality-NGS DNA Capture (EuroClonality-NDC) assay was designed as an integrated tool to characterize these alterations by capturing IGH switch regions along with variable, diversity, and joining genes of all IG and TCR loci in addition to clinically relevant genes for CNA and mutation analysis. Diagnostic performance against standard-of-care clinical testing was assessed in a cohort of 280 B- and T-cell malignancies from 10 European laboratories, including 88 formalin-fixed paraffin-embedded samples and 21 reactive lesions. DNA samples were subjected to the EuroClonality-NDC protocol in 7 EuroClonality-NGS laboratories and analyzed using a bespoke bioinformatic pipeline. The EuroClonality-NDC assay detected B-cell clonality in 191 (97%) of 197 B-cell malignancies and T-cell clonality in 71 (97%) of 73 T-cell malignancies. Limit of detection (LOD) for IG/TCR rearrangements was established at 5% using cell line blends. Chromosomal translocations were detected in 145 (95%) of 152 cases known to be positive. CNAs were validated for immunogenetic and oncogenetic regions, highlighting their novel role in confirming clonality in somatically hypermutated cases. Single-nucleotide variant LOD was determined as 4% allele frequency, and an orthogonal validation using 32 samples resulted in 98% concordance. The EuroClonality-NDC assay is a robust tool providing a single end-to-end workflow for simultaneous detection of B- and T-cell clonality, translocations, CNAs, and sequence variants.

[1]  A. Mosca,et al.  Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes , 2020, Cancers.

[2]  R. Emerson,et al.  Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma , 2020, BMC Cancer.

[3]  M. Salto‐Tellez,et al.  A novel next generation sequencing approach to improve sarcoma diagnosis , 2020, Modern Pathology.

[4]  A. Rosenwald,et al.  Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Stamatopoulos,et al.  Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study , 2019, Leukemia.

[6]  K. Stamatopoulos,et al.  Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS , 2019, Leukemia.

[7]  K. Stamatopoulos,et al.  Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS , 2019, Leukemia.

[8]  B. Tops,et al.  Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics , 2019, Virchows Archiv.

[9]  W. Ou,et al.  Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives. , 2018, Oncology letters.

[10]  Trevor J Pugh,et al.  CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. , 2018, Blood advances.

[11]  Ryan D. Morin,et al.  High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. , 2018, Blood advances.

[12]  N. López-Bigas,et al.  CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase , 2018, Leukemia.

[13]  V. Seshan,et al.  Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay , 2018, Blood Cancer Journal.

[14]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[15]  R. Fulton,et al.  A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5 , 2018, Blood Cancer Journal.

[16]  H. Dombret,et al.  TCRα rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome , 2018, Leukemia.

[17]  D. Rossi,et al.  The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. , 2017, Hematology. American Society of Hematology. Education Program.

[18]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[19]  T. Jacques,et al.  Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours , 2017, bioRxiv.

[20]  K. Stamatopoulos,et al.  High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges , 2017, The Journal of Immunology.

[21]  K. Stamatopoulos,et al.  Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing , 2017, Haematologica.

[22]  Martin Demko,et al.  ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data , 2016, Bioinform..

[23]  M. Ladetto,et al.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Ash A. Alizadeh,et al.  Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA , 2016, Science Translational Medicine.

[25]  A. Hoischen,et al.  Reliable Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue Using Single Molecule Tags. , 2016, The Journal of molecular diagnostics : JMD.

[26]  R. Suzuki,et al.  A new high-throughput sequencing method for determining diversity and similarity of T cell receptor (TCR) α and β repertoires and identifying potential new invariant TCR α chains , 2016, BMC Immunology.

[27]  Alex M. Fichtenholtz,et al.  Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. , 2016, Blood.

[28]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[29]  G. Morgan,et al.  Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. , 2013, Blood.

[30]  Dereje D. Jima,et al.  The genetic landscape of mutations in Burkitt lymphoma , 2012, Nature Genetics.

[31]  E. Schuuring,et al.  EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations , 2012, Leukemia.

[32]  Hugo Y. K. Lam,et al.  Performance comparison of exome DNA sequencing technologies , 2011, Nature Biotechnology.

[33]  A Collins,et al.  13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia , 2011, Leukemia.

[34]  Douglas Chesher,et al.  Evaluating assay precision. , 2008, The Clinical biochemist. Reviews.

[35]  T. Molina,et al.  Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 , 2007, Leukemia.

[36]  J. V. van Dongen,et al.  Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. , 2004, Blood.

[37]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[38]  Ming Zhou,et al.  Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor , 2003, Genes, chromosomes & cancer.

[39]  D. Catovsky,et al.  Delineation of the minimal region of loss at 13q14 in multiple myeloma , 2003, Genes, chromosomes & cancer.

[40]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Werner,et al.  Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas , 2000, Leukemia.

[42]  M. Ladanyi,et al.  ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). , 2000, The American journal of pathology.